Among them, Amgen’s sotorasib (AMG510) was approved by the FDA in May 2021 for patients with KRAS G12C-mutated non-small cell lung cancer and is the first KRAS-targeted drug marketed worldwide. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.